GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal Metastases
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This study will test the safety of the study drug, GDC-0084, in combination with radiation
therapy in people who have solid tumor brain metastases or leptomeningeal metastases. All
participants will have cancer with a PIK3CA mutation. The researchers will test increasing
doses of GDC-0084 to find the highest dose that causes few or mild side effects in
participants. The study will also try to find out if the combination of the study drug with
radiation is effective against participants' cancer.